Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension

Circulation

Volumn 100, Issue 16, 1999, Pages 1680-1683

  Taddei, Stefano ^a   Virdis, Agostino ^a   Ghiadoni, Lorenzo ^a   Sudano, Isabella ^a   Notari, Massimo ^b   Salvetti, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b TAKEDA Italia Farmaceutici SpA   (Italy)

Author keywords

Endothelin; Hypertension; Nitric oxide; Vasodilation

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; NORADRENALIN; TAK 044; VASODILATOR AGENT;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FOREARM BLOOD FLOW; HUMAN; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; VASOCONSTRICTION; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 0033584711     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.16.1680     Document Type: Article

References (18)

1. Yanagisawa M, Kurihawa H, Kimura S, Tomobe Y, Koboyashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332: 411-415.
2. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990; 348:730-732.
3. Seo B, Oemar BS, Siebermann R, Segesser L, Luscher T. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89:1203-1208.
4. Tsukahara H, Ende H, Magazine HI, Bahou WF, Gologorsky MS. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells: receptor coupling to nitric oxide synthase. J Biol Chem. 1994;269:21778-21785.
5. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998;16:1081-1098.
6. Krum H, Viskoper RJ, Lacourcière Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338: 784-790.
7. Watanabe T, Awane Y, Ikeda S, Fujiwara S, Kubo K, Kikuchi T, Kusumoto K, Wakimasu M, Fujino M. Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044, and the inhibition of myocardial infarct size in rats. Br J Pharmacol. 1995;114:949-954.
8. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222-2229.
9. Ikeda S, Awane Y, Kusumoto K, Wakimasu M, Watanabe T, Fujino M. A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA- and ETB-mediated blood pressure responses in rats. J Pharmacol Exp Ther. 1994;270:728-733.
10. Ferro CJ, Haynes WG, Johnston NR, Lomax CC, Newby DE, Webb DJ. The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction. Br J Clin Pharmacol. 1997;44:377-383.
11. Haynes WG, Ferro CJ, O'Kane KPJ, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996;93: 1860-1870.
12. Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol. 1989;96:418-424.
13. Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet. 1989;333: 991-992.
14. Davenport AP, Ashby MJ, Easton P, Ella S, Bedford J, Dickerson C. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci. 1990;78:261-264.
15. Yoshimoto S, Ishizaki Y, Sasaki T, Murota SI. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke. 1991;22:378-383.
16. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 1998;97:752-756.
17. G-monomethyl-L-arginine in patients with essential hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992;10: 1025-1031.
18. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO III, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999;33:753-758.